Sanofi
Latest Sanofi News and Updates
Novo Nordisk’s Business Model: An Overview
Novo Nordisk’s (NVO) business model includes a portfolio in areas such as diabetes, hemophilia, and growth hormones. In the first half of 2015, diabetes care accounted for 78.6% of its total revenues.
AbbVie’s Endocrinology, Cardiovascular, and Rare Disease Segments
AbbVie has a diversified offering of drugs for the treatment of conditions related to endocrinology, cardiovascular, and rare disease.
Why Abbott’s Business Is Susceptible to Numerous Risks
Abbott deals with innovative devices and established pharmaceutical products. Any infringement of intellectual property rights may lead to huge losses.
Biogen: Positive 2Q15 Results for Multiple Sclerosis Pipeline Drugs
In 2Q15, Biogen (BIIB) posted mixed results for its pipeline drugs. Investor sentiment remained favorable for its innovative multiple sclerosis (or MS) drugs.
Sanofi’s Position Compared to Its Peers
The forward PE ratio for Sanofi is ~15.1x for 2015, and ~18.1x for the industry.
Sanofi’s Segment-Wise Sales by Region
Sanofi (SNY) products are sold in over 120 countries. The company’s markets are classified into four geographical regions for reporting purposes.
Biogen’s Geographic Market Strategy
In 2014, Biogen earned about 27% of its total revenues from international markets such as Canada, Europe, and emerging economies.
Risks for GlaxoSmithKline
GSK operates in over 170 countries and is subject to political, socioeconomic, and financial factors and risks across the globe.
Comparing GlaxoSmithKline with Its Peers
Pharmaceutical companies like GlaxoSmithKline are capital-intensive, with high debt on their balance sheets due to heavy setup costs and huge research and development expenses.
What Risks Does Eli Lilly and Company Face?
The risk of losing market share due to losing patents is the highest risk that Eli Lilly and other pharmaceutical companies face.
What Are the Risks for Bristol-Myers Squibb?
Bristol-Myers Squibb deals with innovative products, and any failure to secure or protect intellectual property rights is a huge risk and may lead to huge losses.